Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
Become a Member | Sign in
Home>News>This Article

Flow Technologies in Bioscience Review

Published: Monday, October 29, 2012
Last Updated: Monday, October 29, 2012
Bookmark and Share
The conference highlighted the importance of collaboration between chemists, biologists, material scientists, IT and mechanical engineers, and of course equipment vendors to increase the effectiveness of flow technologies within Bioscience.

Microsaic Systems presented at ‘Flow Technologies in Bioscience’ organised by Labstract and held at the newly opened Stevenage Bioscience Catalyst Innovation centre.

Suki Klair, CEO at Labstract organised a stimulating agenda of speakers with a focus on enabling new applications via flow technologies.

Steve Jordan, Head of R&D, Biotage chaired the event and set the scene by commenting that continuous processing was gaining ground within the pharma industry and welcomed the speakers who ranged from academic thought leaders in flow, including Professor Steve Haswell, University of Hull, to equipment vendors including Microsaic Systems.

Many people are still on the fence about the benefits of flow chemistry, and in some cases it doesn’t make sense to change processes that are working in batch. However, as chemists search for more novel transformations they are forced to look at hazardous transformations such as ozonolysis and diazotisation and this is where flow chemistry can provide significant safety improvements to batch methods. Flow technology is here to stay. It will not replace batch chemistry but it does provide another tool in the chemist’s tool box.

Syrris highlighted a compelling example of this from the BOSS group in Rio de Janeiro where flow through a biocatalyst had increased catalyst efficiency by 10 times, compared to batch. They also mentioned a new electrochemistry module that will be available next year. Electrochemistry is a lost art so a database of reactions will be built up by key users and shared by Syrris on their website.

Matt O’Brien, Keele University talked about his time in the Ley lab, University of Cambridge where gas-liquid reactions have been successfully performed safely in flow with hazardous gases such as ozone using the innovative tube-in-a-tube reactors available from Uniqsis and Cambridge Reactor Design.

Bryan McCullough, Microsaic showed the first example of mass spectrometry being used to monitor a flow reaction which was jointly published with the Ley group, University of Cambridge. Mass spectrometry is not new, but the new miniature MS, the MiD fits in a fumehood, giving chemists access to this useful technique. Both Mettler Toledo, manufacturer of the Flow-IR and Microsaic showed that using on-line monitoring can greatly increase reaction understanding. The Ley group uses these technologies to increase the speed of reaction optimisation and identify new reaction intermediates and pathways.

Chris Selway gave us an insight into what is happening at Cyclofluidic. Their novel synthesis platform allows compounds to be synthesised from a set of pre-loaded monomers, purified, analysed, and then injected into a biological assay. Their algorithm “learns” which compounds are most potent and the computer decides which compound to make next. Each cycle takes 1 hour and over a weekend a candidate compound can be found. This is “closing the loop” of drug discovery, enabled by flow technologies.

Professor Steve Haswell, University of Hull is at the cutting edge of lab-on-a-chip technologies and highlighted the potential use of functionalised microfluidic devices that could be used by police and doctors for point-of-use applications. It was interesting to hear that regulatory bodies are positive about these new, disruptive technologies and actually the barrier-to-entry is the institutions who will resist change, in spite of cost and time savings.

Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,100+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
Mass Spec Technology Drives Innovation Across the Biopharma Workflow
With greater resolving power, analytical speed, and accuracy, new mass spectrometry technology and techniques are infiltrating the biopharmaceuticals workflow.
Targeting Cannabinoid CB2 Receptors in the CNS
With endogenous cannabinoids considered as a potential target to combat CNS diseases, this article examines the role of CB2R could play in fighting some disorders.
Bacterial Genes Boost Current in Human Cells
Borrowing and tweaking bacterial genes to enhance electrical activity might treat heart, nervous system injury.
Less Frequent Cervical Cancer Screening
HPV-vaccinated women may only need one screening every 5 to 10 years with screening starting later in life.
Cocoa Compound Linked to Some Cardiovascular Biomarker Improvements
The study highlights the urgent need for large, long-term RCTs that improve understanding of how the short-term benefits of cocoa flavanol intake on cardiometabolic biomarkers may be translated into clinical outcomes.
Untangling a Cause of Memory Loss in Neurodegenerative Diseases
The mouse study identifies a possible therapeutic target for a family of disorders.
New Pathway for COPD Biomarker Development
A study from Philip Morris International has highlighted multi-lipid profiling as a potential new pathway for COPD biomarker development.
Stiffening a Blow to Cancer Cells
Researchers develop a way to predict how a tumor tissue's physical properties affect its response to chemotherapy drugs.
Anti-Cancer Drug Uses Tumour mRNA to Identify Responders
Phase I study of novel anti-cancer drug uses tumour mRNA expression to identify patients who will respond to the drug.
New Strategy for Choosing Cancer Drugs
Device can predict tumor responses by measuring cell growth after drug exposure.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,100+ scientific videos